PolyPid (PYPD) Competitors

PolyPid logo
$6.63 +0.09 (+1.31%)
As of 10:05 AM Eastern
This is a fair market value price provided by Massive. Learn more.

PYPD vs. EOLS, OCS, AQST, ASMB, and RLMD

Should you buy PolyPid stock or one of its competitors? PolyPid's main competitors and comparable companies include Evolus (EOLS), Oculis (OCS), Aquestive Therapeutics (AQST), Assembly Biosciences (ASMB), and Relmada Therapeutics (RLMD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does PolyPid compare to Evolus?

Evolus (NASDAQ:EOLS) and PolyPid (NASDAQ:PYPD) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, media sentiment, profitability, earnings and risk.

Evolus presently has a consensus price target of $15.00, indicating a potential upside of 124.22%. PolyPid has a consensus price target of $11.67, indicating a potential upside of 78.39%. Given Evolus' higher probable upside, research analysts clearly believe Evolus is more favorable than PolyPid.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Evolus
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50
PolyPid
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

Evolus has a beta of 1.38, indicating that its share price is 38% more volatile than the broader market. Comparatively, PolyPid has a beta of 1.43, indicating that its share price is 43% more volatile than the broader market.

PolyPid has lower revenue, but higher earnings than Evolus. Evolus is trading at a lower price-to-earnings ratio than PolyPid, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evolus$297.18M1.49-$51.64M-$0.47N/A
PolyPidN/AN/A-$34.17M-$1.35N/A

90.7% of Evolus shares are held by institutional investors. Comparatively, 26.5% of PolyPid shares are held by institutional investors. 5.0% of Evolus shares are held by company insiders. Comparatively, 24.7% of PolyPid shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, PolyPid had 8 more articles in the media than Evolus. MarketBeat recorded 24 mentions for PolyPid and 16 mentions for Evolus. Evolus' average media sentiment score of 0.75 beat PolyPid's score of 0.47 indicating that Evolus is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Evolus
4 Very Positive mention(s)
1 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
PolyPid
5 Very Positive mention(s)
3 Positive mention(s)
7 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

PolyPid has a net margin of 0.00% compared to Evolus' net margin of -9.56%. Evolus' return on equity of 0.00% beat PolyPid's return on equity.

Company Net Margins Return on Equity Return on Assets
Evolus-9.56% N/A -11.10%
PolyPid N/A -410.49%-123.13%

Summary

Evolus beats PolyPid on 8 of the 14 factors compared between the two stocks.

How does PolyPid compare to Oculis?

Oculis (NASDAQ:OCS) and PolyPid (NASDAQ:PYPD) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership.

Oculis has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market. Comparatively, PolyPid has a beta of 1.43, meaning that its share price is 43% more volatile than the broader market.

PolyPid has a net margin of 0.00% compared to Oculis' net margin of -8,613.92%. Oculis' return on equity of -39.24% beat PolyPid's return on equity.

Company Net Margins Return on Equity Return on Assets
Oculis-8,613.92% -39.24% -33.45%
PolyPid N/A -410.49%-123.13%

PolyPid has lower revenue, but higher earnings than Oculis. PolyPid is trading at a lower price-to-earnings ratio than Oculis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oculis$1.45M300.30-$119.44M-$1.71N/A
PolyPidN/AN/A-$34.17M-$1.35N/A

22.3% of Oculis shares are owned by institutional investors. Comparatively, 26.5% of PolyPid shares are owned by institutional investors. 24.7% of PolyPid shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Oculis currently has a consensus price target of $38.57, suggesting a potential upside of 413.60%. PolyPid has a consensus price target of $11.67, suggesting a potential upside of 78.39%. Given Oculis' stronger consensus rating and higher possible upside, equities research analysts clearly believe Oculis is more favorable than PolyPid.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oculis
1 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.75
PolyPid
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

In the previous week, PolyPid had 16 more articles in the media than Oculis. MarketBeat recorded 24 mentions for PolyPid and 8 mentions for Oculis. Oculis' average media sentiment score of 0.76 beat PolyPid's score of 0.47 indicating that Oculis is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Oculis
2 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
PolyPid
5 Very Positive mention(s)
3 Positive mention(s)
7 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Oculis beats PolyPid on 8 of the 15 factors compared between the two stocks.

How does PolyPid compare to Aquestive Therapeutics?

PolyPid (NASDAQ:PYPD) and Aquestive Therapeutics (NASDAQ:AQST) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.

PolyPid has higher earnings, but lower revenue than Aquestive Therapeutics. Aquestive Therapeutics is trading at a lower price-to-earnings ratio than PolyPid, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PolyPidN/AN/A-$34.17M-$1.35N/A
Aquestive Therapeutics$44.54M10.44-$83.78M-$0.64N/A

PolyPid has a beta of 1.43, suggesting that its share price is 43% more volatile than the broader market. Comparatively, Aquestive Therapeutics has a beta of 1.49, suggesting that its share price is 49% more volatile than the broader market.

26.5% of PolyPid shares are held by institutional investors. Comparatively, 32.5% of Aquestive Therapeutics shares are held by institutional investors. 24.7% of PolyPid shares are held by insiders. Comparatively, 6.8% of Aquestive Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, PolyPid had 19 more articles in the media than Aquestive Therapeutics. MarketBeat recorded 24 mentions for PolyPid and 5 mentions for Aquestive Therapeutics. Aquestive Therapeutics' average media sentiment score of 1.06 beat PolyPid's score of 0.47 indicating that Aquestive Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
PolyPid
5 Very Positive mention(s)
3 Positive mention(s)
7 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Aquestive Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive

PolyPid has a net margin of 0.00% compared to Aquestive Therapeutics' net margin of -162.33%. Aquestive Therapeutics' return on equity of 0.00% beat PolyPid's return on equity.

Company Net Margins Return on Equity Return on Assets
PolyPidN/A -410.49% -123.13%
Aquestive Therapeutics -162.33%N/A -57.35%

PolyPid currently has a consensus price target of $11.67, indicating a potential upside of 78.39%. Aquestive Therapeutics has a consensus price target of $8.75, indicating a potential upside of 136.49%. Given Aquestive Therapeutics' higher possible upside, analysts plainly believe Aquestive Therapeutics is more favorable than PolyPid.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PolyPid
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
Aquestive Therapeutics
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

Summary

Aquestive Therapeutics beats PolyPid on 8 of the 12 factors compared between the two stocks.

How does PolyPid compare to Assembly Biosciences?

PolyPid (NASDAQ:PYPD) and Assembly Biosciences (NASDAQ:ASMB) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, media sentiment, dividends, valuation and earnings.

PolyPid currently has a consensus target price of $11.67, suggesting a potential upside of 78.39%. Assembly Biosciences has a consensus target price of $46.50, suggesting a potential upside of 106.67%. Given Assembly Biosciences' higher probable upside, analysts plainly believe Assembly Biosciences is more favorable than PolyPid.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PolyPid
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
Assembly Biosciences
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50

In the previous week, PolyPid had 17 more articles in the media than Assembly Biosciences. MarketBeat recorded 24 mentions for PolyPid and 7 mentions for Assembly Biosciences. PolyPid's average media sentiment score of 0.47 beat Assembly Biosciences' score of -0.77 indicating that PolyPid is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
PolyPid
5 Very Positive mention(s)
3 Positive mention(s)
7 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Assembly Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Negative

Assembly Biosciences has higher revenue and earnings than PolyPid. PolyPid is trading at a lower price-to-earnings ratio than Assembly Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PolyPidN/AN/A-$34.17M-$1.35N/A
Assembly Biosciences$72.30M6.37-$6.12M$0.8127.78

PolyPid has a beta of 1.43, meaning that its share price is 43% more volatile than the broader market. Comparatively, Assembly Biosciences has a beta of 1.26, meaning that its share price is 26% more volatile than the broader market.

PolyPid has a net margin of 0.00% compared to Assembly Biosciences' net margin of -16.57%. Assembly Biosciences' return on equity of -4.40% beat PolyPid's return on equity.

Company Net Margins Return on Equity Return on Assets
PolyPidN/A -410.49% -123.13%
Assembly Biosciences -16.57%-4.40%-3.86%

26.5% of PolyPid shares are held by institutional investors. Comparatively, 19.9% of Assembly Biosciences shares are held by institutional investors. 24.7% of PolyPid shares are held by insiders. Comparatively, 3.5% of Assembly Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Assembly Biosciences beats PolyPid on 8 of the 14 factors compared between the two stocks.

How does PolyPid compare to Relmada Therapeutics?

PolyPid (NASDAQ:PYPD) and Relmada Therapeutics (NASDAQ:RLMD) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

PolyPid is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PolyPidN/AN/A-$34.17M-$1.35N/A
Relmada TherapeuticsN/AN/A-$57.38M-$0.72N/A

PolyPid presently has a consensus price target of $11.67, suggesting a potential upside of 78.39%. Relmada Therapeutics has a consensus price target of $12.00, suggesting a potential upside of 298.67%. Given Relmada Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Relmada Therapeutics is more favorable than PolyPid.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PolyPid
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
Relmada Therapeutics
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.75

Relmada Therapeutics' return on equity of -37.25% beat PolyPid's return on equity.

Company Net Margins Return on Equity Return on Assets
PolyPidN/A -410.49% -123.13%
Relmada Therapeutics N/A -37.25%-34.87%

26.5% of PolyPid shares are held by institutional investors. Comparatively, 45.2% of Relmada Therapeutics shares are held by institutional investors. 24.7% of PolyPid shares are held by company insiders. Comparatively, 14.5% of Relmada Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

PolyPid has a beta of 1.43, meaning that its share price is 43% more volatile than the broader market. Comparatively, Relmada Therapeutics has a beta of 0.62, meaning that its share price is 38% less volatile than the broader market.

In the previous week, PolyPid had 3 more articles in the media than Relmada Therapeutics. MarketBeat recorded 24 mentions for PolyPid and 21 mentions for Relmada Therapeutics. Relmada Therapeutics' average media sentiment score of 0.78 beat PolyPid's score of 0.47 indicating that Relmada Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
PolyPid
5 Very Positive mention(s)
3 Positive mention(s)
7 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Relmada Therapeutics
3 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Relmada Therapeutics beats PolyPid on 10 of the 14 factors compared between the two stocks.

Get PolyPid News Delivered to You Automatically

Sign up to receive the latest news and ratings for PYPD and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PYPD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PYPD vs. The Competition

MetricPolyPidPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$126.42M$13.51B$7.69B$11.70B
Dividend YieldN/A2.58%2.47%4.46%
P/E Ratio-4.9128.8633.9829.89
Price / SalesN/A7.298.475.70
Price / CashN/A15.6321.0121.89
Price / Book33.135.414.483.75
Net Income-$34.17M$2.88B$3.51B$393.66M
7 Day Performance0.39%-4.47%-5.55%-5.43%
1 Month Performance40.38%-4.86%-4.18%-6.76%
1 Year Performance82.03%-7.02%-1.56%-7.01%

PolyPid Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PYPD
PolyPid
3.1735 of 5 stars
$6.63
+1.3%
$11.67
+76.1%
+80.2%$126.42MN/AN/A72
EOLS
Evolus
3.2156 of 5 stars
$6.81
-2.4%
$15.00
+120.3%
-3.7%$461.99M$297.18MN/A353
OCS
Oculis
2.8336 of 5 stars
$7.59
-2.2%
$37.38
+392.4%
-60.8%$449.96M$1.45MN/A60
AQST
Aquestive Therapeutics
2.3191 of 5 stars
$3.52
-0.6%
$8.75
+148.6%
-36.4%$444.93M$44.54MN/A147
ASMB
Assembly Biosciences
1.9116 of 5 stars
$21.35
-2.0%
$46.50
+117.8%
-38.1%$443.66M$72.30M20.9373

Related Companies and Tools


This page (NASDAQ:PYPD) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners